Pharmackinetics/pharmacodynamics of ceftazidime-avibactam in adult critically ill patients receiving continuous renal replacement therapy

Ceftazidime-avibactam (CAZ-AVI), a novel antibiotic, is effective in treating infections caused by carbapenem-resistant Gram-negative bacteria. However, in patients receiving continuous renal replacement therapy (CRRT), both the pharmacokinetics(PK) and pharmacodynamics(PD) of the drugs can be significantly altered. Currently, there remains a lack of clear guidelines regarding optimal dosing regimens for CAZ-AVI during CRRT. Prospectively, this study evaluated the PK/PD of CAZ-AVI in 21 critically ill patients receiving CRRT. We collected blood samples at 5-7 sampling points within one administration cycle, and then determined the total plasma drug concentrations. Phoenix was used to calculate the PK parameters. The clearance at steady-state (CLss) of patients receiving CRRT was significantly reduced, and drug exposure was also significantly increased compared to healthy subjects. Notably, four patients demonstrated the free minimum plasma concentrations (fCmin) of CAZ exceeding eight t..., , # Pharmackinetics/pharmacodynamics of ceftazidime-avibactam in adult critically ill patients receiving continuous renal replacement therapy

Dataset DOI: [10.5061/dryad.fxpnvx16s](https://doi.org/10.5061/dryad.fxpnvx16s)

## Description of the data and file structure

```
This dataset contains prospective pharmacokinetic and clinical data from 21 critically ill patients receiving ceftazidime-avibactam antibiotic therapy while undergoing continuous renal replacement therapy (CRRT). The study aimed to characterize drug exposure and clearance patterns to inform optimal dosing strategies in this complex patient population. Data include serial drug concentration measurements, CRRT parameters, microbial susceptibility testing, treatment outcomes, and patient characteristics.
```

### Files and variables

#### File: Demographic_data.csv

**Description:** Demographic and clinical characteristics of study participants

##### Variables

* subjectID:  anonymized subject identifier
* age_year: Age ..., I confirm that we received explicit consent from our participants to publish the de-identified data in the public domain. We did not disclose the personal privacy of the subjects, such as names and ID numbers. Instead, we used anonymized subject numbers to represent different individual patients.